[Inhibition of Non-Receptor Tyrosine Kinase JAK2 Reduces Neuroblastoma Cell Growth and Enhances the Action of Doxorubicin].

Lebedev, T D; Vagapova, E R; Astashkova, O O; Spirin, P V; Prassolov, V S

Lebedev, T D; Vagapova, E R; Astashkova, O O; Spirin, P V; Prassolov, V S.

Afiliação

Lebedev TD; Enhelgardt Institute of Molecular Biology Russian Ðcademy of Science, Moscow, 119991 Russia.
Vagapova ER; Enhelgardt Institute of Molecular Biology Russian Ðcademy of Science, Moscow, 119991 Russia.
Astashkova OO; Enhelgardt Institute of Molecular Biology Russian Ðcademy of Science, Moscow, 119991 Russia.
Spirin PV; Enhelgardt Institute of Molecular Biology Russian Ðcademy of Science, Moscow, 119991 Russia.
Prassolov VS; Enhelgardt Institute of Molecular Biology Russian Ðcademy of Science, Moscow, 119991 Russia.

Mol Biol (Mosk) ; 54(2): 293-299, 2020.

Article em Ru | MEDLINE | ID: mdl-32392199

Assuntos

Doxorrubicina/farmacologia; Janus Quinase 2/antagonistas & inibidores; Neuroblastoma/patologia; Ciclo Celular; Linhagem Celular Tumoral; Humanos; Janus Quinase 2/metabolismo; Fosforilação; Transdução de Sinais; Tirfostinas/farmacologia

Palavras-chave

JAK2; Janus kinase 2; breast cancer; combination therapy; doxorubicin; glioblastoma; malignant diseases; neuroblastoma; non-small cell lung cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doxorrubicina / Janus Quinase 2 / Neuroblastoma Limite: Humans Idioma: Ru Revista: Mol Biol (Mosk) Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google